Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02287064
Other study ID # SCA IVIG 2014
Secondary ID
Status Recruiting
Phase Phase 1
First received November 5, 2014
Last updated June 6, 2016
Start date April 2015

Study information

Verified date June 2016
Source University of South Florida
Contact Mary Freeman, LPN
Phone 813-974-5909
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to learn how Intravenous Immune Globulin (IVIG) will affect Spinocerebellar Ataxia (SCA) symptoms and how it will affect motor and nervous system function in participants Subtypes of SCA to be examined will include SCA types 1, 2, 3, 6, 10 and 11.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Outpatients with SCA types 1, 2, 3, 6, 10, or 11, diagnosed by a movement disorder specialist.

- Age 18 years to 80 years.

- Able to ambulate with or without assistance for 30 feet.

- Women of child-bearing potential must use a reliable method of contraception and must provide a negative pregnancy test at entry into the study.

- Serum creatine kinase, complete metabolic panel, complete blood count, liver function tests, renal function tests, platelets and EKG do not reveal clinically significant abnormalities (results obtained from primary care physician and dated within the past 6 months or obtained at screening visit).

- Stable doses of all medications for 30 days prior to study entry and for the duration of the study.

- Diagnosis of peripheral neuropathy. See exclusion criteria 3 for specific types of peripheral neuropathy to be excluded.

- Throughout the study, all possible efforts will be made to maintain subject levels of activity, exercise or physical therapy.

- Subject permission (informed consent).

Exclusion Criteria:

- Any unstable illness that in the investigator's opinion precludes participation in this study.

- Use of any investigational product within the past 30 days.

- Presence of diabetes (as determined by blood glucose labs within the past 6 months), nutritional deficiency causing neuropathy (vitamin B1, 3, 6, and 12 or vitamin E), injuries, autoimmune disorders (HIV, lupus, pediatric Guillain-Barre syndrome, neurosarcoidosis, monoclonal gammopathy), tumors, infections (leprosy), exposures to toxins (alcohol, arsenic, mercury), thyroid disease or hereditary causes (cerebral amyloid angiopathy) known to result in the presence of peripheral neuropathy.

- Dementia or other psychiatric illness that prevents the subject from giving informed consent (MMSE less than 25).

- Legal incapacity or limited legal capacity.

- Presence of severe renal disease (estimated creatinine clearance <50 mL/min) or hepatic disease (as evidenced by labs reported within the past 6 months).

- Clinically significantly abnormal white blood cell count, hemoglobin or platelet count (as evidenced by labs reported within the past 6 months).

- Immunoglobulin A, Vitamin B (1, 3, 6, or 12), vitamin E or folate deficiencies (evidenced by screening lab evaluations).

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Intravenous Immune Globulin (IVIG)
IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month. There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from "induction dose" IVIG (2 g/kg) continued each month, than with the "booster dose" maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion

Locations

Country Name City State
United States University of South Florida Tampa Florida

Sponsors (2)

Lead Sponsor Collaborator
University of South Florida Baxter Healthcare Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Scale for the Assessment and Rating Ataxia (SARA) The primary outcomes will be the changes in the patient's SARA total score and frequency and severity of adverse events. Will be assesed at abseline, day 14, day28 and day 56. Yes
Secondary clinician and patient global impression of improvement (CGI and PGI) Secondary outcome measures will include changes in the following scales between baseline and study endpoint: clinician and patient global impression of improvement (CGI and PGI); neurologic dysfunction as assessed by STAND scores; 9-hole peg test times. Will be assesed at abseline, day 14, day28 and day 56. No
Secondary Neurologic dysfunction as assessed by STAND scores Secondary outcome measures will include changes in the following scales between baseline and study endpoint: clinician and patient global impression of improvement (CGI and PGI); neurologic dysfunction as assessed by STAND scores; 9-hole peg test times. Will be assesed at abseline, day 14, day28 and day 56. No
Secondary 9-hole peg test Secondary outcome measures will include changes in the following scales between baseline and study endpoint: clinician and patient global impression of improvement (CGI and PGI); neurologic dysfunction as assessed by STAND scores; 9-hole peg test times. Will be assesed at abseline, day 14, day28 and day 56. No
See also
  Status Clinical Trial Phase
Recruiting NCT05973019 - rTMS Improves Functions in Spinocerebellar Ataxia N/A
Completed NCT04837027 - Effect of Training on Brain Volume in Ataxia N/A
Completed NCT04595578 - Cerebellar rTMS and Physical Therapy for Cerebellar Ataxia N/A
Completed NCT03745248 - Aerobic Exercise, Balance Training, and Ataxia N/A
Completed NCT05951010 - Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia 38 N/A
Completed NCT01037777 - RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7
Completed NCT00136630 - Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
Completed NCT03687190 - Could Tai-chi Help Maintain Balance of Spinocerebellar Ataxia Patients N/A
Active, not recruiting NCT03701399 - Troriluzole in Adult Subjects With Spinocerebellar Ataxia Phase 3
Completed NCT05436262 - Using Real-time fMRI Neurofeedback and Motor Imagery to Enhance Motor Timing and Precision in Cerebellar Ataxia N/A
Recruiting NCT04231487 - Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders
Withdrawn NCT04301284 - Study of CAD-1883 for Spinocerebellar Ataxia Phase 2
Not yet recruiting NCT06397274 - Stemchymal® for Polyglutamine Spinocerebellar Ataxia Phase 2
Not yet recruiting NCT06177626 - Impact of Exercise on Eyeblink Conditioning in Spinocerebellar Ataxias N/A
Recruiting NCT04529252 - Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases
Completed NCT05621200 - Transcranial Alternating Current Stimulation (tACS) in Patients With Ataxia N/A
Completed NCT03701776 - Ataxia and Exercise Disease Using MRI and Gait Analysis N/A
Completed NCT03120013 - Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia N/A
Active, not recruiting NCT03408080 - Open Pilot Trial of BHV-4157 Phase 3
Active, not recruiting NCT02960893 - Trial in Adult Subjects With Spinocerebellar Ataxia Phase 2/Phase 3